<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027074</url>
  </required_header>
  <id_info>
    <org_study_id>2060-007</org_study_id>
    <secondary_id>2020-002397-27</secondary_id>
    <secondary_id>MK-2060-007</secondary_id>
    <nct_id>NCT05027074</nct_id>
  </id_info>
  <brief_title>Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (Factor XI Hemodialysis Study) (MK-2060-007)</brief_title>
  <official_title>A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two different doses of&#xD;
      MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD)&#xD;
      participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study&#xD;
      will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is&#xD;
      that at least one of the MK-2060 doses is superior to placebo in increasing the time to first&#xD;
      occurrence of AVG event.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">April 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First AVG Thrombosis Event</measure>
    <time_frame>From date of randomization until the date of first occurrence of an AVG thrombosis event, assessed up to approximately 17 months</time_frame>
    <description>An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. This endpoint will be adjudicated by an independent clinical adjudication committee (CAC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of AVG Thrombosis Events</measure>
    <time_frame>Up to approximately 17 months</time_frame>
    <description>An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. This endpoint will be adjudicated by an independent CAC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experience One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 20 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Major Bleeding Events or Clinically Relevant Non-Major Bleeding Events per International Society on Thrombosis (ISTH) Criteria</measure>
    <time_frame>Up to approximately 20 months</time_frame>
    <description>Major bleeding events will be defined as having a symptomatic presentation and including one or more of the following criteria: 1) Fatal bleeding 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intramuscular with compartment syndrome, 3) Bleeding causing a decrease in hematocrit level of 20 g/L or more or leading to transfusion of 2 or more units of whole blood or red cells.&#xD;
Clinically relevant non-major bleeding events will be defined as having signs or symptoms of hemorrhage that do not meet the criteria for major bleeding events, but do meet at least 1 of the following criteria: 1) Requiring medical intervention by a healthcare professional 2) Leading to hospitalization or increased level of care 3) Prompting a face to face evaluation by a healthcare professional.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Study Intervention Due to an AE</measure>
    <time_frame>Up to approximately 17 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">489</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <condition>End-Stage Kidney Disease</condition>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>MK-2060 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-2060 low dose administered via intravenous (IV) infusion as a loading dose: Every other day (QOD) during week 1 (3 administrations), then once a week (QW) after week 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-2060 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-2060 high dose administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then QW after week 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then once a week after week 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2060</intervention_name>
    <description>MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion</description>
    <arm_group_label>MK-2060 High Dose</arm_group_label>
    <arm_group_label>MK-2060 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline administered via IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of ESRD.&#xD;
&#xD;
          -  Receiving hemodialysis ≥3 times per week with each hemodialysis session being a&#xD;
             minimum of 3 hours duration via a normally functioning, uninfected AVG for at least 4&#xD;
             weeks.&#xD;
&#xD;
          -  A female participant is not pregnant or breastfeeding, not a woman of child-bearing&#xD;
             potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance during the&#xD;
             intervention period and for at least 90 days after the last dose of study&#xD;
             intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent history of cancer (&lt;1 year). Non-melanoma skin cancers are allowed.&#xD;
&#xD;
          -  Mechanical/prosthetic heart valve.&#xD;
&#xD;
          -  Recent hemorrhagic stroke or lacunar stroke (&lt;1 month).&#xD;
&#xD;
          -  Recent evidence (&lt;1 month) of bleeding requiring hospitalization or unplanned medical&#xD;
             attention, a history (≤2 years) of recurrent bleeding episodes including epistaxis,&#xD;
             gastrointestinal (GI) bleeds or genitourinary (GU) bleeds requiring medical treatment&#xD;
             or events requiring treatment with blood products.&#xD;
&#xD;
          -  Recent history (&lt;1 year) of drug or alcohol abuse or dependence.&#xD;
&#xD;
          -  Currently receiving or planning to receive anticoagulants or antiplatelet medications.&#xD;
&#xD;
          -  Planning on receiving a living donor renal transplant within 12 months (participants&#xD;
             are permitted to be candidates for deceased donor renal transplants).&#xD;
&#xD;
          -  Planning on receiving an arteriovenous fistula (AVF) placement within 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Citrus Dialysis Center ( Site 0609)</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-797-1695</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita West Glendale Dialysis ( Site 0579)</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>866-544-6741</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Puente Dialysis Center ( Site 0610)</name>
      <address>
        <city>La Puente</city>
        <state>California</state>
        <zip>91744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-797-1695</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Research Institute ( Site 0533)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-725-7149</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North America Research Institute ( Site 0587)</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-797-1695</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North America Research Institute ( Site 0612)</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-797-1695</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Renal Medical Group Research-Clinical Research ( Site 0651)</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91343</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>818-886-7300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Desert Cities Diaylsis-Clinical Research ( Site 0615)</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92392</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>760-998-2060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elixia at Florida Kidney Physicians - Southeast ( Site 0602)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-493-9774</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Florida Research Institute ( Site 0656)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-739-4474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research ( Site 0605)</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-435-9990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omega Research MetroWest ( Site 0645)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-998-1075</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research ( Site 0585)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>813-755-4400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research ( Site 0594)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>813-755-4400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research ( Site 0680)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>813-873-1016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Durham Nephrology Associates ( Site 0655)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-477-3005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Carolina Nephrology &amp; Hypertension Center-Research ( Site 0672)</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>803-531-2220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Institute for Kidney and Endocrine Disorders ( Site 0626)</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>936-632-4282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Health-Sunshine &amp; Footscray Hospitals-Renal Services ( Site 0054)</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61383451333</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

